Biotech News

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

BMYBristol-Myers Squibb Company (BMY)BMYBristol-Myers Squibb Company2026-06-25 13:46 ESTEarnings

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

June 18, 2026

Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2026 on Thursday, July 30, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:15 a.m. ET.

Investors and the general public are invited to listen to a live audio webcast of the call at http://investor.bms.com . Materials related to the call will be available on the company’s Investor Relations website prior to the start of the conference call.

A replay of the webcast will be available here approximately three hours after the conference call concludes.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn , X , YouTube , Facebook and Instagram .

corporatefinancial-news

Source: Bristol Myers Squibb

Media downloads:

Categories: Press Releases

Open original release

Related news

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

BMYBMYBristol-Myers Squibb Company2026-06-25 13:46 EST

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

BMYBMYBristol-Myers Squibb Company2026-06-25 13:46 EST

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

BMYBMYBristol-Myers Squibb Company2026-06-25 13:46 EST

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

BMYBMYBristol-Myers Squibb Company2026-06-25 13:46 EST

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

BMYBMYBristol-Myers Squibb Company2026-06-25 13:46 EST

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BMYBMYBristol-Myers Squibb Company2026-06-25 13:46 EST

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

BMYBMYBristol-Myers Squibb Company2026-06-25 13:46 EST

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

BMYBMYBristol-Myers Squibb Company2026-06-25 13:46 EST

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

BMYBMYBristol-Myers Squibb Company2026-06-25 13:46 EST

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

BMYBristol-Myers Squibb Company

Bristol Myers Squibb is a large-cap biopharmaceutical company with a portfolio spanning oncology, hematology, immunology, and cardiovascular disease. The market watches the stock for commercial durability, pipeline replacement, and the pace at which new assets offset lifecycle pressure.

Recent company news

Stock data

Close
57.58 USD
Market cap
117.58B USD
Exchange
NYSE
Sector
Biopharmaceuticals
Location
Princeton, New Jersey